Trials / Unknown
UnknownNCT02586402
Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis
A Phase 2, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Pegolsihematide for the Correction of Anemia in Patients With CRF Undergoing Dialysis and Previously Treated With ESAs
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of multiple intravenous doses of pegol-Sihematide in participants with chronic kidney disease (CKD) who are on dialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pegol-Sihematide | |
| DRUG | Epoetin Alfa |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2015-10-26
- Last updated
- 2015-10-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02586402. Inclusion in this directory is not an endorsement.